Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 226

The DOI matches its Crossref record.

Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure

Stoiser, B., Mörtl, D., Hülsmann, M., Berger, R., Struck, J., Morgenthaler, N. G., Bergmann, A., Pacher, R. · 2006 · European Journal of Clinical Investigation

Abstract

Background Natriuretic peptides, particularly brain natriuretic peptide (BNP), are elevated in heart failure and therefore considered to be excellent predictors of outcome. Vasopressin is also known to be related to the severity of heart disease. Copeptin – an inactive fragment of the vasopressin precursor – has not been previously investigated in the context of heart failure. Materials and methods We prospectively studied 268 patients with advanced heart failure after they had been discharged from the hospital. We investigated the ability of BNP and copeptin to predict death, re‐hospitalization due to heart failure, and a combination of the two endpoints. Results Over a mean follow‐up period of 15·8 months (up to 24 months), 83 patients died, 122 patients experienced worsening of heart failure, and 145 patients achieved the combined endpoint. Univariate predictors of death were copeptin, BNP, age and impaired kidney function. In multivariate analysis, copeptin (χ 2 = 16,P < 0·0001) and age (χ 2 = 4,P < 0·05) were independent predictors. Univariate predictors of re‐hospitalization due to heart failure were copeptin, BNP, age and impaired kidney function. Furthermore, in multivariate analysis BNP (χ 2 = 18,P < 0·0001), age (χ 2 = 11·8,P < 0·001) and copeptin (χ 2 = 4·2,P < 0·05) were found to be independent predictors. Conclusion Our study is the first to show that copeptin is an excellent predictor of outcome in advanced heart failure patients. Its value is superior to that of BNP in predicting death and a combined endpoint, although BNP is still suitable for predicting chronic heart failure (CHF) re‐hospitalization. Our data imply that vasopressin antagonism might be a new target to improve outcome in this population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2362.2006.01724.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 226

Metadata

Authors
Stoiser, B., Mörtl, D., Hülsmann, M., Berger, R., Struck, J., Morgenthaler, N. G., Bergmann, A., & Pacher, R.
Venue
European Journal of Clinical Investigation
Publisher
Wiley
Published
2006-10-09
Volume
36
Issue
11
Pages
771-778
ISSN
  • 0014-2972 (ISSN-L)
  • 1365-2362
OpenAlex
W2167996222
Cited by
226
References
0
FWCI
5.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. https://app.cochat.ai/papers/10.1111/j.1365-2362.2006.01724.x
The paper
Stoiser, B., Mörtl, D., Hülsmann, M., Berger, R., Struck, J., Morgenthaler, N. G., Bergmann, A., & Pacher, R. (2006). Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. European Journal of Clinical Investigation. https://doi.org/10.1111/j.1365-2362.2006.01724.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.